Replies to post #103 on Dyax Corp. (DYAX)

[surf1944]

7:44AM Dyax announced presentation of data from Kalbitor clinical studies: low rebound and relapse rates observed (DYAX) 1.46 : Henry Li, M.D., Ph.D. of the Institute for Asthma and Allergy in Wheaton, MD said, "Taken together, the results presented today enrich the KALBITOR efficacy profile and provide further support for its use against acute attacks of hereditary angioedema. Notably, low rebound and relapse rates observed among patients treated with KALBITOR evidence sustained relief from HAE attacks, an important consideration in selecting therapy